At the news
? NEUTRALIMPACT 3/10 8-K filed Aug 18, 2026 at 06:03 ET
Haemonetics entered into a non-exclusive supply agreement with CSL Plasma for use of its NexSys PCS devices and disposables in the U.S. No minimum purchase commitments; scope and timing of transition are undetermined. The company is not updating its fiscal 2027 guidance and will provide an update on the expected impact during its second fiscal quarter earnings call in November 2026.
- Non-exclusive supply agreement with CSL Plasma Inc. signed August 14, 2026.
- CSL may utilize Haemonetics' NexSys PCS devices with Persona PLUS technology and purchase related disposables in the U.S.
- The agreement contains no minimum purchase commitments.
- Scope and timing of CSL's center transitions have not yet been determined.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access